1Hideshima T,Chauhan D,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J].Blood,2000,96(9):2943
2Davies FE,Raje N,Hideshima T,et al.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma[J].Blood,2001,98(1):210
3Munshi NC,Decikan R K,Barlogie B.Clinical experience with thalidomide in multiple myeloma:phase Ⅱ trial results in referactory disease and ongoing studies[J].Semin Hematol,2000,37(Suppl 3):15
4Barlogie B,Desikan R,Eddlemon P,et al.Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide:identification of prognostic factors in a phase 2 study of 169 patients[J].Blood,2001,98(2):492
